Effect of Background Diuretic Therapy on the Clinical Efficacy of SGLT2 Inhibitors in Patients of Heart Failure with Reduced Ejection Fraction: Current Evidence

Authors

  • Dr KAMAL KISHOR Rama Superspeciality and Critical Care Hospital, Karnal, Haryana, India
  • Dr DEVENDRA SINGH BISHT Head, Dept. of Cardiology, Mukat Hospital and Heart Institute, Chandigarh, Punjab, India
  • Dr ASHOK KUMAR Head, CEDAR Clinic, Panipat, Haryana, India

Keywords:

SGLT2 inhibitors, heart failure,, DELIVER,, EMPEROR-Reduced

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a fundamental therapy for heart failure with reduced ejection fraction
(HFrEF). The clinical efficacy of SGLT2 inhibitors in the presence of background diuretic therapy has been questioned, mainly
because of the overlapping diuretic mechanism of action. However, recently, data analysis from two landmark trials, DELIVER
and EMPEROR-Reduced, has attempted to settle this question. Both analyses demonstrate a consistent benefit of SGLT2
inhibitors across a wide range of background diuretic therapy. This brief communication sheds light on the key findings from
these scientific studies

Published

2024-09-14

How to Cite

Dr KAMAL KISHOR, Dr DEVENDRA SINGH BISHT, & Dr ASHOK KUMAR. (2024). Effect of Background Diuretic Therapy on the Clinical Efficacy of SGLT2 Inhibitors in Patients of Heart Failure with Reduced Ejection Fraction: Current Evidence. Indian Journal Of Clinical Practice, 35(4), 35–36. Retrieved from https://ojs.ijcp.in/?journal=IJCP&page=article&op=view&path[]=1113

Issue

Vol. 35 No. 4 (2024)

Section

Brief Communication
Copyright & Licensing